



***The potential impact of the Taskforce
recommendations on a UK T-cell
therapy SME***

Jim Faulkner
BioProcess UK,
November 2016

www.autolus.com , j.faulkner@autolus.com

Company factsheet

- Ambition to build a fully integrated engineered T cell company
- Founded in September 2014, as a spin-off of University College London (UCL)
- Key founder: Dr. Martin Pulé
- Capital raised: £70 million
- Over 65 employees and growing
- Collaborations with leading UK academic and clinical centres
- Company is located in London, UK
- Expect to have three programs enter clinical trials in 2017



Key Recommendations

- Strengthen and secure an internationally **competitive fiscal landscape** to attract investment
- Target and capture internationally mobile investments through a proactive and **simplified process of engagement**
- **Maintain science and innovation funding** to support industry developing cutting-edge technologies
- **Set out an end-to-end talent management plan** to secure the relevant skills for emerging manufacturing technologies
- Clearly set out a swift, predictable and **viable route to market** for these innovative products and give industry confidence that the UK is a progressive global hub
- Develop a long-term regulatory strategy and plan for the **MHRA to lead in global standards**, supporting the scientific activities and international outreach of NIBSC